Literature DB >> 25527218

The current status of imaging in anti-NGF clinical trials.

C G Miller1, A Guermazi2, F Roemer3.   

Abstract

Keywords:  Anti-NGF; Anti-nerve growth factor; Clinical trials; Medical imaging; Radiology; X-ray; aNGF

Mesh：

Substances：

Year:  2015        PMID： 25527218     DOI： 10.1016/j.joca.2014.09.002

Source DB:  PubMed          Journal:  Osteoarthritis Cartilage        ISSN： 1063-4584            Impact factor:   6.576


× No keyword cloud information.
  7 in total

Review 1.  Nerve Growth Factor Antagonists: Is the Future of Monoclonal Antibodies Becoming Clearer?

Authors:  Bernard Bannwarth; Marie Kostine
Journal:  Drugs       Date:  2017-09       Impact factor: 9.546

2.  Retrograde nerve growth factor signaling modulates tooth mechanical hyperalgesia induced by orthodontic tooth movement via acid-sensing ion channel 3.

Authors:  Meiya Gao; Xinyu Yan; Yanzhu Lu; Linghuan Ren; Shizhen Zhang; Xiaoqi Zhang; Qianyun Kuang; Lu Liu; Jing Zhou; Yan Wang; Wenli Lai; Hu Long
Journal:  Int J Oral Sci       Date:  2021-06-04       Impact factor: 6.344

Review 3.  Mechanisms of Osteoarthritic Pain. Studies in Humans and Experimental Models.

Authors:  Annett Eitner; Gunther O Hofmann; Hans-Georg Schaible
Journal:  Front Mol Neurosci       Date:  2017-11-03       Impact factor: 5.639

Review 4.  Nerve growth factor antibody for the treatment of osteoarthritis pain and chronic low-back pain: mechanism of action in the context of efficacy and safety.

Authors:  Martin Schmelz; Patrick Mantyh; Anne-Marie Malfait; John Farrar; Tony Yaksh; Leslie Tive; Lars Viktrup
Journal:  Pain       Date:  2019-10       Impact factor: 7.926

5.  Tanezumab for chronic low back pain: a randomized, double-blind, placebo- and active-controlled, phase 3 study of efficacy and safety.

Authors:  John D Markman; Robert B Bolash; Timothy E McAlindon; Alan J Kivitz; Manuel Pombo-Suarez; Seiji Ohtori; Frank W Roemer; David J Li; Lars Viktrup; Candace Bramson; Christine R West; Kenneth M Verburg
Journal:  Pain       Date:  2020-09-01       Impact factor: 7.926

6.  Subcutaneous tanezumab for osteoarthritis of the hip or knee: efficacy and safety results from a 24-week randomised phase III study with a 24-week follow-up period.

Authors:  Francis Berenbaum; Francisco J Blanco; Ali Guermazi; Kenji Miki; Takaharu Yamabe; Lars Viktrup; Rod Junor; William Carey; Mark T Brown; Christine R West; Kenneth M Verburg
Journal:  Ann Rheum Dis       Date:  2020-03-31       Impact factor: 19.103

7.  General Safety and Tolerability of Subcutaneous Tanezumab for Osteoarthritis: A Pooled Analysis of Three Randomized, Placebo-Controlled Trials.

Authors:  Francis Berenbaum; Thomas J Schnitzer; Alan J Kivitz; Lars Viktrup; Anne Hickman; Glenn Pixton; Mark T Brown; Isabelle Davignon; Christine R West
Journal:  Arthritis Care Res (Hoboken)       Date:  2022-03-25       Impact factor: 5.178
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.